
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZFP62 (ZFP62 zinc finger protein) encodes a zinc finger protein predicted to bind zinc ions and participate in regulation of transcription by RNA polymerase II. Its predicted nuclear activity is consistent with a role in transcriptional regulation and control of gene expression. ZFP62 may therefore contribute to cellular processes governed by RNA polymerase II-dependent transcription.
The U-87 MG cell line was derived from a malignant glioma of a female patient using an explant technique by J. Ponten and colleagues between 1966 and 1969. This human glioblastoma model has been extensively characterized and is reported to form malignant tumors consistent with glioblastoma in nude mice. U-87 MG is widely used in neuro-oncology research as an in vitro model for studying glioma biology, tumor growth mechanisms, cancer cell signaling, and evaluation of therapeutic strategies for malignant brain tumors.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_001172638
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?